search
Back to results

Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity

Primary Purpose

Acanthosis Nigricans

Status
Unknown status
Phase
Phase 4
Locations
Mexico
Study Type
Interventional
Intervention
Metformin
Placebo
Sponsored by
Juan Pablo Castanedo-Cazares
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acanthosis Nigricans focused on measuring Acanthosis nigricans, obesity, children, metformin

Eligibility Criteria

8 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed informed consent from children and parents.
  • Children younger than 18 years.
  • Clinical diagnosis of acanthosis nigricans.
  • Obesity.

Exclusion Criteria:

  • Diabetes mellitus.
  • Neurological diseases.
  • Congenital diseases.
  • Oral treatment for obesity in the last two months.
  • Topical treatment for the last two months.

Sites / Locations

  • Hospital Central Dr.Ignacio Morones Prieto

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Metformin

Placebo

Arm Description

500 mg metformin oral intake before main meal

Placebo tablet before main meal.

Outcomes

Primary Outcome Measures

Clinical improvement of acanthosis nigricans
Initial and after intervention assessment of acanthosis nigricans using the quantitative scale of Burke (Diabetes Care 22:1655-1659, 1999). Five anatomical sites were chosen to assess the presence and extent of AN: neck, axilla, knuckles, elbows, and knees. The neck and axilla are graded for severity on a scale from 0 to 4. For AN present on the neck, texture of the affected area is also measured on a scale from 0 to 3. Knuckles, elbows, and knees are graded as AN present (1) or absent (0). Score goes from 0 to 14.

Secondary Outcome Measures

Histological improvement of acanthosis nigricans
Epidermal and stratum corneum thickness of 3 mm skin samples obtained from neck will be measured using an image processing software initially and at the end of trial.
Depigmentation of acanthosis nigricans
Quantification of pigmentation change of lesions by means of the L axis of the CIE system. 0 is pure white, 100 y total dark. Initially, and at the end of study.

Full Information

First Posted
May 3, 2015
Last Updated
May 5, 2015
Sponsor
Juan Pablo Castanedo-Cazares
Collaborators
Hospital Central "Dr. Ignacio Morones Prieto"
search

1. Study Identification

Unique Protocol Identification Number
NCT02438020
Brief Title
Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity
Official Title
Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity
Study Type
Interventional

2. Study Status

Record Verification Date
May 2015
Overall Recruitment Status
Unknown status
Study Start Date
June 2015 (undefined)
Primary Completion Date
June 2016 (Anticipated)
Study Completion Date
October 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Juan Pablo Castanedo-Cazares
Collaborators
Hospital Central "Dr. Ignacio Morones Prieto"

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Obesity is often accompanied by insulin resistance and/or hyperinsulinemia. Acanthosis nigricans (AN) is a skin condition commonly present on the neck of obese children. Metformin is a useful drug for conditions characterized by insulin resistance.The aim of this study is to compare the efficacy of metformin versus placebo on AN lesions of the neck as well as their effects on metabolic and anthropometric variables in a sample of obese children. This is a 12-week randomized, double-blind randomized trial involving obese children with AN to receive either metformin or placebo. Evaluations will be performed every three weeks. Clinical, histological and colorimetric assessments of AN lesions will be compared initially and at the conclusion of the study.
Detailed Description
Acanthosis nigricans (AN) are lesions affecting localized areas of the skin in persons with obesity and/or hyperinsulinemia. Roughening of the skin is related with histological papillomatosis and the skin darkening is due to hyperkeratosis. Biochemical mechanisms for developing this hyperplastic lesion involve local cutaneous growth factors. Nearly 40% of Native American teenagers have acanthosis nigricans, whereas about 13% of African American, 6% of Hispanic, and less than 1% of white, non-Hispanic children aged 10-19 have clinically apparent acanthosis nigricans. AN is a clinical surrogate of laboratory-documented hyperinsulinemia. The aim of this study is to compare the efficacy of metformin versus placebo on AN lesions of the neck as well as their effects on metabolic (HOMA, triglycerides, cholesterol) and anthropometric variables (BMI, waist) in a sample of obese children. This is a 12-week randomized, double-blind randomized trial involving obese children with AN to receive either metformin or placebo. Evaluations will be performed every three weeks. Clinical, histological and colorimetric assessments of AN lesions will be compared initially and at the conclusion of the study. Burke´s scale, papillomatosis and hyperkeratosis, and the L* axis of will be used to measure the AN improvement.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acanthosis Nigricans
Keywords
Acanthosis nigricans, obesity, children, metformin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Metformin
Arm Type
Experimental
Arm Description
500 mg metformin oral intake before main meal
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo tablet before main meal.
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
Glucophage, Glumetza, Fortamet, Riomet
Intervention Description
One tablet of 500 mg will be ingested before the main meal
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
A placebo tablet will be ingested daily before main meal.
Primary Outcome Measure Information:
Title
Clinical improvement of acanthosis nigricans
Description
Initial and after intervention assessment of acanthosis nigricans using the quantitative scale of Burke (Diabetes Care 22:1655-1659, 1999). Five anatomical sites were chosen to assess the presence and extent of AN: neck, axilla, knuckles, elbows, and knees. The neck and axilla are graded for severity on a scale from 0 to 4. For AN present on the neck, texture of the affected area is also measured on a scale from 0 to 3. Knuckles, elbows, and knees are graded as AN present (1) or absent (0). Score goes from 0 to 14.
Time Frame
baseline and 12 weeks
Secondary Outcome Measure Information:
Title
Histological improvement of acanthosis nigricans
Description
Epidermal and stratum corneum thickness of 3 mm skin samples obtained from neck will be measured using an image processing software initially and at the end of trial.
Time Frame
baseline and 12 weeks
Title
Depigmentation of acanthosis nigricans
Description
Quantification of pigmentation change of lesions by means of the L axis of the CIE system. 0 is pure white, 100 y total dark. Initially, and at the end of study.
Time Frame
baseline and 12 weeks
Other Pre-specified Outcome Measures:
Title
Serum fasting insulin
Description
Quantification of serum fasting insulin in pmol/L or mIU/L, at baseline and at the end of the study.
Time Frame
baseline and 12 weeks
Title
Serum fasting glucose
Description
Quantification of serum fasting glucose in mg/dL.
Time Frame
baseline and 12 weeks
Title
Serum fasting lipids
Description
Quantification of serum fasting lipids in mg/dL. Cholesterol (HDL, LDL, VLDL) and triglycerides.
Time Frame
baseline and 12 weeks
Title
Waist measurement
Description
Waist measurement in centimeters.
Time Frame
baseline and 12 weeks
Title
Quantification of Body mass index (BMI)
Description
BMI It is the measure of body fat based on height and weight. The BMI is the body mass divided by the square of the body height, and expressed in units of kg/m2, resulting from weight in kilograms and height in metres
Time Frame
baseline and 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed informed consent from children and parents. Children younger than 18 years. Clinical diagnosis of acanthosis nigricans. Obesity. Exclusion Criteria: Diabetes mellitus. Neurological diseases. Congenital diseases. Oral treatment for obesity in the last two months. Topical treatment for the last two months.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Juan P Castanedo-Cazares, MD
Phone
524448342795
Email
castanju@yahoo.com
First Name & Middle Initial & Last Name or Official Title & Degree
Francisco Goldaracena-Orozco, MD
Phone
524448342795
Email
goldarac@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bertha Torres-Alvarez, MD
Organizational Affiliation
Hospital Central "Dr. Ignacio Morones Prieto"
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Juan P Castanedo-Cazares, MD
Organizational Affiliation
Hospital Central "Dr. Ignacio Morones Prieto"
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Francisco Goldaracena-Orozco, MD
Organizational Affiliation
Hospital Central "Dr. Ignacio Morones Prieto"
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Central Dr.Ignacio Morones Prieto
City
San Luis Potosi
State/Province
SLP
ZIP/Postal Code
78210
Country
Mexico

12. IPD Sharing Statement

Citations:
PubMed Identifier
17039655
Citation
Bellot-Rojas P, Posadas-Sanchez R, Caracas-Portilla N, Zamora-Gonzalez J, Cardoso-Saldana G, Jurado-Santacruz F, Posadas-Romero C. Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study. J Drugs Dermatol. 2006 Oct;5(9):884-9.
Results Reference
background
PubMed Identifier
11335776
Citation
Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001 Apr;107(4):E55. doi: 10.1542/peds.107.4.e55.
Results Reference
background
PubMed Identifier
18492785
Citation
Romo A, Benavides S. Treatment options in insulin resistance obesity-related acanthosis nigricans. Ann Pharmacother. 2008 Jul;42(7):1090-4. doi: 10.1345/aph.1K446. Epub 2008 May 20.
Results Reference
background

Learn more about this trial

Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity

We'll reach out to this number within 24 hrs